{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T05:08:39Z","timestamp":1790485719653,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Hungarian Government","award":["VKSZ 12-1-2013-0012"],"award-info":[{"award-number":["VKSZ 12-1-2013-0012"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.ijcard.2019.03.013","type":"journal-article","created":{"date-parts":[[2019,3,15]],"date-time":"2019-03-15T03:46:41Z","timestamp":1552621601000},"page":"47-52","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"special_numbering":"C","title":["Risk prediction model for long-term heart failure incidence after epirubicin chemotherapy for breast cancer \u2013 A real-world data-based, nationwide classification analysis"],"prefix":"10.1016","volume":"285","author":[{"given":"Gy\u00f6rgy","family":"Fogarassy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1gnes","family":"Vathy-Fogarassy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Istv\u00e1n","family":"Kenessey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikl\u00f3s","family":"K\u00e1sler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam\u00e1s","family":"Forster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2019.03.013_bb0005","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1001\/jama.294.10.1255","article-title":"Trends in the leading causes of death in the United States, 1970\u20132002","volume":"294","author":"Jemal","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2019.03.013_bb0010","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1093\/annonc\/mdu131","article-title":"Effects of newly developed chemotherapy regimens, comorbidities, chemotherapy-related toxicities on the changing patterns of the leading causes of death in elderly patients with colorectal cancer","volume":"25","author":"Tong","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ijcard.2019.03.013_bb0015","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ijcard.2010.03.003","article-title":"Cardiac side-effects of cancer chemotherapy","volume":"144","author":"Monsuez","year":"2010","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2019.03.013_bb0020","first-page":"e32","article-title":"Drugs that may cause or exacerbate heart failure: a scientific statement from the American Heart Association","volume":"9","author":"Page","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2019.03.013_bb0025","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.115.002661","article-title":"Cancer therapy-related cardiac dysfunction and heart failure: part 1: definitions, pathophysiology, risk factors, and imaging","volume":"9","author":"Bloom","year":"2016","journal-title":"Circ. Heart Fail."},{"key":"10.1016\/j.ijcard.2019.03.013_bb0030","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3322\/caac.21341","article-title":"Cardiotoxicity of anticancer treatments: epidemiology, detection, and management, CA","volume":"66","author":"Curigliano","year":"2016","journal-title":"Cancer J. Clin."},{"key":"10.1016\/j.ijcard.2019.03.013_bb0035","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","article-title":"Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy","volume":"131","author":"Cardinale","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2019.03.013_bb0040","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1038\/nm.2919","article-title":"Identification of the molecular basis of doxorubicin-induced cardiotoxicity","volume":"18","author":"Zhang","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.ijcard.2019.03.013_bb0045","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s10549-015-3437-9","article-title":"Clinical and genetic risk factors for epirubicin-induced cardiac toxicity in early breast cancer patients","volume":"152","author":"Vulsteke","year":"2015","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.ijcard.2019.03.013_bb0050","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/bcp.13008","article-title":"Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity","volume":"82","author":"Aminkeng","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ijcard.2019.03.013_bb0055","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1002\/cncr.28256","article-title":"Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemia","volume":"119","author":"Lipshultz","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.ijcard.2019.03.013_bb0060","first-page":"4545","article-title":"Prevalence of hemochromatosis-associated mutations in the hemochromatosis gene in the Danish population","volume":"164","author":"Larsen","year":"2002","journal-title":"Ugeskr. Laeger"},{"key":"10.1016\/j.ijcard.2019.03.013_bb0065","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1046\/j.1365-2141.1998.01037.x","article-title":"Prevalence of the C282Y and H63D mutations in the HFE gene in patients with hereditary haemochromatosis and in control subjects from Northern Germany","volume":"103","author":"Nielsen","year":"1998","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ijcard.2019.03.013_bb0070","article-title":"Cardioprotective interventions for cancer patients receiving anthracyclines","volume":"15","author":"van Dalen","year":"2011","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ijcard.2019.03.013_bb0075","doi-asserted-by":"crossref","first-page":"710","DOI":"10.7326\/0003-4819-91-5-710","article-title":"Risk factors for doxorubicin-induced congestive heart failure","volume":"91","author":"Von Hoff","year":"1979","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ijcard.2019.03.013_bb0080","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1016\/j.ejca.2006.08.005","article-title":"Clinical heart failure in a cohort of children treated with anthracyclines: a long-term follow-up study","volume":"42","author":"van Dalen","year":"2006","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ijcard.2019.03.013_bb0085","doi-asserted-by":"crossref","first-page":"3502","DOI":"10.1200\/JCO.1998.16.11.3502","article-title":"Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer","volume":"16","author":"Ryberg","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijcard.2019.03.013_bb0090","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/cncr.11407","article-title":"Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials","volume":"97","author":"Swain","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.ijcard.2019.03.013_bb0095","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1093\/annonc\/mdf118","article-title":"Frequency and risk factors of anthracycline-induced clinical heart failure in children: a systematic review","volume":"13","author":"Kremer","year":"2002","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ijcard.2019.03.013_bb0100","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s10549-007-9803-5","article-title":"The development of a predictive model to estimate cardiotoxic risk for patients with metastatic breast cancer receiving anthracyclines","volume":"107","author":"Dranitsaris","year":"2008","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.ijcard.2019.03.013_bb0105","doi-asserted-by":"crossref","first-page":"3808","DOI":"10.1200\/JCO.2006.10.4976","article-title":"Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer","volume":"25","author":"Pinder","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijcard.2019.03.013_bb0110","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1002\/sim.1742","article-title":"Presentation of multivariate data for clinical use: the Framingham study risk score functions","volume":"23","author":"Sullivan","year":"2004","journal-title":"Stat. Med."},{"key":"10.1016\/j.ijcard.2019.03.013_bb0115","doi-asserted-by":"crossref","first-page":"4265","DOI":"10.1200\/JCO.2005.04.173","article-title":"Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group","volume":"23","author":"Marty","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijcard.2019.03.013_bb0120","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1081\/CNV-100000150","article-title":"Doxorubicin and paclitaxel in the treatment of advanced breast cancer: efficacy and cardiac considerations","volume":"19","author":"Perez","year":"2001","journal-title":"Cancer Investig."},{"key":"10.1016\/j.ijcard.2019.03.013_bb0125","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.ctrv.2013.03.005","article-title":"Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: a systematic review of incidence, manifestations and predisposing factors","volume":"39","author":"Polk","year":"2013","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.ijcard.2019.03.013_bb0130","doi-asserted-by":"crossref","first-page":"453","DOI":"10.5603\/CJ.2012.0084","article-title":"5-fluorouracil induced cardiotoxicity: review of the literature","volume":"19","author":"Sorrentino","year":"2012","journal-title":"Cardiol. J."},{"key":"10.1016\/j.ijcard.2019.03.013_bb0135","first-page":"41","article-title":"Capecitabine-related cardiotoxicity: recognition and management","volume":"6","author":"Saif","year":"2008","journal-title":"J. Support. Oncol."},{"key":"10.1016\/j.ijcard.2019.03.013_bb0140","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1536\/ihj.54.417","article-title":"Capecitabine induces both cardiomyopathy and multifocal cerebral leukoencephalopathy","volume":"54","author":"Endo","year":"2013","journal-title":"Int. Heart J."},{"key":"10.1016\/j.ijcard.2019.03.013_bb0145","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1093\/eurjhf\/hfr165","article-title":"Detection, monitoring, and management of trastuzumab-induced left ventricular dysfunction: an actual challenge","volume":"14","author":"Tocchetti","year":"2012","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ijcard.2019.03.013_bb0150","doi-asserted-by":"crossref","first-page":"3422","DOI":"10.1200\/JCO.2009.26.0463","article-title":"Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial","volume":"28","author":"Procter","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijcard.2019.03.013_bb0155","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1200\/JCO.2015.61.8413","article-title":"Long-term cardiac safety analysis of NCCTG N9831 (alliance) adjuvant trastuzumab trial","volume":"34","author":"Advani","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijcard.2019.03.013_bb0160","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1200\/JCO.2010.31.9129","article-title":"Congestive heart failure risk in patients with breast cancer treated with bevacizumab","volume":"29","author":"Choueiri","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.ijcard.2019.03.013_bb0165","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/ejhf.1168","article-title":"Long-term effect of epirubicin on incidence of heart failure in women with breast cancer: insight from a randomized clinical trial","volume":"20","author":"Banke","year":"2018","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ijcard.2019.03.013_bb0170","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1161\/CIRCULATIONAHA.106.635144","article-title":"Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition","volume":"114","author":"Cardinale","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2019.03.013_bb0175","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/ejhf.654","article-title":"2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines, the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)","volume":"19","author":"Zamorano","year":"2017","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ijcard.2019.03.013_bb0180","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/ejhf.196","article-title":"Protective effects of spironolactone against anthracycline-induced cardiomyopathy","volume":"17","author":"Akpek","year":"2015","journal-title":"Eur. J. Heart Fail."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016752731835873X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016752731835873X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T20:42:11Z","timestamp":1759092131000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016752731835873X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":36,"alternative-id":["S016752731835873X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2019.03.013","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk prediction model for long-term heart failure incidence after epirubicin chemotherapy for breast cancer \u2013 A real-world data-based, nationwide classification analysis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2019.03.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}